Dividend
A second interim dividend of $2.17 per share (159.5 pence, 19.49 SEK) has been declared, resulting in a full-year dividend per share of $3.20.
Other highlights:
* Total Revenue up 8% to $58,739m, driven by Oncology, CVRM, R&I and Rare Disease
* Growth in Total Revenue across all major geographic regions
* Core Operating profit increased 9%
* Core EPS increased 11% to $9.16
* Second interim dividend declared of $2.17 per share (159.5 pence, 19.49 SEK). Total dividend declared for FY 2025 increased by 3% to $3.20 per share
* 16 positive Phase 3 readouts and 43 approvals in major regions in the last twelve months
